Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
Rev Neurosci ; 35(1): 57-84, 2024 Jan 29.
Article in English | MEDLINE | ID: mdl-37609845

ABSTRACT

Late in the twentieth century, interest intensified regarding the involvement of the circadian system in the aetiology and treatment of Parkinson's disease (PD). It has been envisaged that this approach might provide relief beyond the limited benefits and severe side effects achieved by dopamine (DA) replacement. In the first clinical article, published in 1996, polychromatic light was used to shift the circadian clock as it is considered to be the most powerful zeitgeber (time keeper) that can be implemented to realign circadian phase. Since that time, 11 additional articles have implemented light treatment (LT) in various forms as an adjuvant to DA replacement. In spite of the growing interest in this area, the systematic exploration of LT in PD has been stymied by several methodological factors. Such factors include time of LT presentation, duration of studies undertaken, frequency of light employed, dose of light prescribed and relevance of experimental design to the prolonged course of the illness. On this basis, it is the purpose of this review to provide an in-depth examination of these papers, and the underlying preclinical work, to provide critique, thereby giving direction for future studies in therapeutic applications of LT for PD. Consideration of this collective work may serve to carve a path for future research and thereby improve the lives of those suffering from this debilitating disorder.


Subject(s)
Parkinson Disease , Humans , Parkinson Disease/drug therapy , Dopamine
2.
Chronobiol Int ; 39(12): 1539-1541, 2022 12.
Article in English | MEDLINE | ID: mdl-36440636

Subject(s)
Circadian Rhythm
3.
Sleep Med ; 44: 24-31, 2018 04.
Article in English | MEDLINE | ID: mdl-29530365

ABSTRACT

Insomnia, hypersomnia and REM Sleep Behavior Disorder (RSBD) during sleep are major problems for patients suffering from Parkinson's disease (PD) but they are also used to predict its onset. While these secondary symptoms detract from the quality of life in PD patients, few treatment options are available due to limited efficacy or risk of complicating the treatment regimen. Light therapy (LT) has been suggested as a strategy for sleep disorders but it has only been implemented recently for use in PD. An open label, retrospective study was undertaken where PD patients had been undergoing LT, using polychromatic light, for four months to 15 years prior. It was found that 1 h exposure to light, just prior to retiring, significantly improved insomnia and reduced RSBD in as little as one month after commencing LT. In addition, the improvement was maintained as long as LT was continued over a four to six year period. The efficacy of LT in alleviating these sleep related conditions was not compromised by time since diagnosis or age of the patient. These results intimate the value of long term application of non-invasive techniques such as LT for treating sleep disorders in PD and justify further controlled trials on the long term efficacy of LT.


Subject(s)
Parkinson Disease/complications , Phototherapy/methods , REM Sleep Behavior Disorder/therapy , Sleep Initiation and Maintenance Disorders/therapy , Aged , Disorders of Excessive Somnolence/therapy , Female , Humans , Longitudinal Studies , Male , Quality of Life , Retrospective Studies
4.
Brain Res ; 1678: 203-213, 2018 Jan 01.
Article in English | MEDLINE | ID: mdl-28958865

ABSTRACT

The importance of circadian function in the aetiology, progression and treatment of Parkinson's disease is a topic of increasing interest to the scientific and clinical community. While clinical studies on this theme are relatively new and limited in number there are many preclinical studies which explore possible circadian involvement in Parkinson's disease and speculate as to the mechanism by which clinical benefit can be derived by manipulating the circadian system. The present review explores the sequelae of circadian related studies from a historical perspective and reveals mechanisms that may be involved in the aetiology and progression of the disease. A systematic review of these studies also sets the stage for understanding the basic neuroscientific approaches which have been applied and provides new direction from which circadian function can be explored.


Subject(s)
Antiparkinson Agents/pharmacology , Circadian Rhythm/drug effects , Drug Evaluation, Preclinical , Parkinson Disease , Animals , Antiparkinson Agents/therapeutic use , Circadian Rhythm/physiology , Humans , Parkinson Disease/drug therapy , Parkinson Disease/etiology , Parkinson Disease/physiopathology
5.
Behav Brain Res ; 339: 232-238, 2018 Feb 26.
Article in English | MEDLINE | ID: mdl-29180132

ABSTRACT

The retina bears embryological, neurochemical and functional similarities to the circadian and dopamine systems of the brain. Recent studies have shown that the intravitreal injection of minute quantities of L-dopa and of the melatonin receptor antagonist ML-23 have anti-Parkinsonian potential. Furthermore, it has been suggested that light therapy may be potentially useful in treating some aspects of Parkinson's disease (PD) and it is hypothesized that this treatment works via the circadian system. Given that little is known about the mechanism by which such treatments work the present study was designed to examine the role of the acetyl cholinergic system of the retina in gross bodily movement. While IVIT atropine was shown to improve movement in intact rats Cogentin treated rats showed impairment of motor function compared to control rats or to rats treated with any other cholinergic drug. Furthermore, a link between the phase of the light/dark cycle and the efficacy of these drugs in altering movement was demonstrated. These results show that anticholinergic systems in the retina can exert control over movement which has been solely attributed to the function of deep brain structures.


Subject(s)
Cholinergic Agents/pharmacology , Circadian Rhythm/drug effects , Levodopa/pharmacology , Motor Activity/drug effects , Animals , Brain/drug effects , Circadian Rhythm/physiology , Dopamine/pharmacology , Male , Parkinson Disease/drug therapy , Rats, Sprague-Dawley
6.
Front Neurol ; 9: 741, 2018.
Article in English | MEDLINE | ID: mdl-30778331

ABSTRACT

Parkinson's disease (PD) is a disorder characterized by loss of dopamine (DA) in the nigro-striatal dopamine (NSD) system with the primary symptoms of bradykinaesia, rigidity, tremor, and altered gate. Secondary symptoms including depression, insomnia, involuntary movement, and psychiatric side effects are also commonly observed. While the treatment focus for the past 50 years has been aimed at replacing deficient DA, to relieve the primary symptoms, more recent studies have suggested that the circadian system plays a critical role in the etiology and treatment of this disorder. Several case studies and open label trials have implemented bright light therapy (BT) in an attempt to repair sleep, depression and even the primary motor symptoms of this disorder, however controlled studies are yet to be fully implemented. In this controlled trial, patients that had been maintained on BT daily for 4 months to 5 years previously were assigned to one of three groups: continued polychromatic light, continued with red light or discontinued polychromatic light for a 2 week period. The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDSUPDRS), The Parkinson's Disease Questionnaire (PDQ-39), The Beck Depression Inventory II, The Beck Anxiety Inventory, The Epworth Sleep Scale (ESS) and a global rating scale were used to assess patients prior to and at 1 and 2 weeks after commencing the trial. Patients continuing polychromatic BT showed significant improvement on the MDSUPDRS Rating Scale (12 points; p = 0.028), the PDQ-39 (10 points; p = 0.011), ESS (4 points; p = 0.013), and numerous motor and secondary symptoms on a global rating scale. Performance on standardized motor tests also incrementally improved in this group while those exposed to red light and those that discontinued BT treatment deteriorated. These results demonstrate that strategically applied polychromatic light was beneficial in reducing many primary motor and secondary symptoms of PD. Further work investigating the role of light in mitigating PD symptoms and involvement of the circadian system will provide further advances in the treatment of PD. Clinical Trial Registration: http://www.anzctr.org.au, identifier ACTRN12617001309370.

7.
Physiol Behav ; 182: 1-9, 2017 Dec 01.
Article in English | MEDLINE | ID: mdl-28919247

ABSTRACT

The role of the circadian system in Parkinson's disease (PD) is a topic of increasing scientific interest. This has emerged from recent studies demonstrating an altered response of PD patients to treatment in relation to the phase of the light/dark cycle and from other work defining the functional significance of melanocytes in PD: a cell type that the nigro-striatal dopamine (NSD) system and circadian system both contain. The present study was undertaken to determine the sensitivity of the pineal, as the final common pathway of the circadian system, to light delivered directly to the pineal via surgical implantation of LEDs. Direct photic stimulation of the pineal altered the course of experimental PD while anatomical controls receiving stimulation of the frontal cortex exhibited a negative impact on the course of recovery of these animals. These effects were closely linked to the phase of the light/dark cycle. The present results suggest that while pineal photoreceptors are regarded as vestigial, functional photo-reactivity of the pineal remains. It is inferred that melanocytes are the active cells responsible for the observed effect since they remain functionally intact in mammalian pineal even though pineal photoreceptors are functionally inert. Although the stimuli applied in the present study may be regarded as artificial this study demonstrates that brain parenchyma remains differentially reactive to direct light exposure and presents a novel mechanism in circadian structures that needs to be explored.


Subject(s)
Light , Parkinsonian Disorders/pathology , Parkinsonian Disorders/physiopathology , Pineal Gland/physiology , Pineal Gland/radiation effects , Animals , Body Weight , Frontal Lobe , Male , Movement/radiation effects , Oxidopamine/toxicity , Parkinsonian Disorders/chemically induced , Photic Stimulation , Rats , Rats, Sprague-Dawley , Sympatholytics/toxicity , Time Factors
8.
Front Neurol ; 8: 324, 2017.
Article in English | MEDLINE | ID: mdl-28725212

ABSTRACT

Recent studies have revealed that the retina may exert control over deep brain function and may be importantly involved in the etiology, progression, and treatment of disorders such as Parkinson's disease (PD). While such a concept is uncharted territory and even less is known about the mechanism by which this might be achieved, this study was undertaken to determine how retinal dopamine (DA), serotonin (5-HT), and melatonin (MEL) neurotransmitter systems might be involved in the control of movement in their own right. To explore these further, intravitreal (IVIT) injections of DA, 5-HT, and MEL were made 0.5 or 3 h prior to testing horizontal and vertical movement in the open field as well as assessment on three motor tests used routinely to evaluate movement as a preclinical model of PD. The doses of DA (2 µl of 25 and 75 µg/µl), 5-HT (2 µl of 5 and 15 µg/µl), and MEL (2 µl of 5 µg/µl) were chosen because of previous work demonstrating an anatomically precise effect of these transmitters after they were injected directly into the brain. The postinjection times of testing were also chosen on the basis of previous intracerebral and IVIT work intimating the importance of the circadian cycle in determining the efficacy of such effects. 0.5 h after IVIT injection of DA at the 25 and 75 µg/µl doses, significant inhibition of motor function was observed. While IVIT injection of 10 or 30 µg of 5-HT also inhibited motor performance, this was significantly less than that seen with DA. In fact, IVIT injection increases motor performance compared to vehicle injection on some parameters. The IVIT injection of 10 µg of MEL facilitated motor function on many parameters compared to DA, 5-HT, and vehicle injection. When rats were tested 3 h after IVIT injection, the inhibition of vertical movement was also observed compared to controls. The present results illustrate that specific retinal neurotransmitter systems participate in the normal control of bodily motor function. The possible involvement of these systems in movement disorders such as PD is the subject of ongoing research.

9.
Mov Disord ; 31(3): 260-9, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26826022

ABSTRACT

The circadian system regulates biological rhythmicity in the human body. The role of the circadian system in neurological disorders is a theme that is attracting an increasing amount of interest from the scientific community. This has arisen, in part, from emerging evidence that disorders such as Parkinson's disease (PD) are multifactorial with many features exhibiting diurnal fluctuations, thereby suggestive of circadian involvement. Although the importance of fluctuating motor and nonmotor manifestations in PD have been well acknowledged, the role of the circadian system has received little attention until recently. It is proposed that intervening with circadian function provides a novel research avenue down which new strategies for improving symptomatic treatment and slowing of the progressive degenerative process can be approached to lessen the burden of PD. In this article we review the literature describing existing circadian research in PD and its experimental models.


Subject(s)
Brain/physiopathology , Circadian Rhythm/physiology , Parkinson Disease/physiopathology , Sleep Wake Disorders/physiopathology , Sleep/physiology , Animals , Disease Models, Animal , Humans , Parkinson Disease/therapy
10.
Sci Rep ; 4: 3921, 2014 Jan 29.
Article in English | MEDLINE | ID: mdl-24473093

ABSTRACT

Critical analysis of recent research suggesting that light pollution causes Parkinson's disease (PD) reveals that such a hypothesis is unsustainable in the context of therapeutic use of light in treating various neuropsychiatric conditions. Reinterpretation of their findings suggests that retinal damage caused by prolonged light exposure may have contributed to the observed enhancement of experimental PD. To test this hypothesis further, forty-two Sprague Dawley rats received microinjections of 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-2, 4, 6-tetrahydropyridine (MPTP), paraquat or rotenone into the vitreal mass in doses so minute that the effects could not be attributed to diffusion into brain. Significant changes in five motor parameters consistent with symptoms of experimental PD were observed. These findings support the interpretation that the retina is involved in the control of motor function and in the aetiology of PD.


Subject(s)
Melanocytes/physiology , Parkinson Disease/physiopathology , Retina/physiopathology , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/pharmacology , Animals , Disease Models, Animal , Female , Light , Male , Melanocytes/drug effects , Motor Activity/drug effects , Motor Activity/physiology , Oxidopamine/pharmacology , Paraquat/pharmacology , Rats , Rats, Sprague-Dawley , Retina/drug effects , Rotenone/pharmacology
11.
Rev Neurosci ; 23(4): 403-28, 2012.
Article in English | MEDLINE | ID: mdl-23089606

ABSTRACT

For the past 40 years Parkinson's disease (PD) has been intrinsically associated with dopamine (DA) deficiency of the nigrostriatal DA system. One of the fundamental strengths of this theoretical approach is based on a presumed relationship between the degree of DA deficiency and the severity of motor impairment in the disease and its models. However, detailed examination of a substantial number of exemplary preclinical and clinical studies reveals that any such interpretation is overoptimistic and suggests that DA deficiency may be merely an epiphenomenon of a larger process underlying this disorder. Such a conclusion is based on numerous examples of miscarriage of basic principles of good scientific practice including (i) failure to thoroughly examine the adverse effects of DA replacement, (ii) drawing of statistical inference without recognising excessive spread of measure thereby lessening the importance of outliers, (iii) confounding independent and dependent variables within the scientific paradigm, (iv) overlooking fundamental principles of modern pharmacology, (v) confusing correlation with causation in linking cause and effect and (vi) disinclination to incorporate conflicting findings thereby infringing the quintessential scientific principle of tertium quid. This review demonstrates the inherent risks and dangers in the incontrovertible defence of DA deficiency theory and serves to address the ethical problems that emerge from the clinical application of scientific findings. There is increasing interest in new directions for PD research by dimming down the current emphasis on the importance of DA deficiency and its replacement. This would provide genuine hope and a new direction for the sufferers of a most debilitating disease.


Subject(s)
Dopamine/deficiency , Parkinson Disease/metabolism , Animals , Brain/diagnostic imaging , Brain/metabolism , Deep Brain Stimulation/methods , Dopamine Agents/therapeutic use , Humans , Neuroimaging , Parkinson Disease/pathology , Parkinson Disease/therapy , Radionuclide Imaging
12.
Rev Neurosci ; 23(2): 199-226, 2012 Mar 01.
Article in English | MEDLINE | ID: mdl-22499678

ABSTRACT

For the past 40 years the primary purpose of therapeutics for Parkinson's disease (PD) has been to replace deficient dopamine (DA) in the nigrostriatal dopamine (NSD) system. Even in the presence of limited efficacy, abundant side effects and impoverished quality of life, the involvement of other systems in the aetiology and treatment of this disorder has been sorely neglected and the excessive use of DA replacement therapy (DART) continues on a global basis. Recent scientific work suggests that the retina plays a major role in NSD function and intimates light therapy in the management of PD. After a thorough review of historical evidence supporting this contention, a retrospective, open-label study on 129 PD patients, whereby they were monitored for a period extending for a few months to eight years, was carried out. Primary motor and non-motor symptoms were monitored using an objectified global rating scale and timed motor tests that were assessed at regular intervals for the duration of the study. Thirty-one patients with other neurological disorders (OND) served as controls to determine whether any therapeutic effects seen with light were generalizable across other conditions. Patients were classified as compliant (COM), semi-compliant (SCOM), or early quit (EQUIT; prematurely discontinued treatment). EQUIT patients showed deterioration, while the COM group improved on most parameters. The SCOM patients were not as good as the COM group. The OND group showed significant improvement in depression and insomnia, but exposure to light did not improve motor function. The total drug burden of PD patients maintained on light was less with fewer side effects than SCOM or EQUIT groups. These results confirm the value of the strategic application of light therapy with controlled doses of DART in PD and warrants further controlled investigation. That the symptomatic improvement continued as long patients remained in the program suggests that exposure to light, under a strict daily regimen, combined with controlled DART, actively slows or arrests the progressive degenerative process underlying PD.


Subject(s)
Dopamine Agonists/adverse effects , Dopamine/metabolism , Melatonin/metabolism , Parkinson Disease/therapy , Phototherapy/methods , Adult , Aged , Aged, 80 and over , Analysis of Variance , Circadian Clocks/physiology , Combined Modality Therapy , Depression/therapy , Dopamine Agonists/therapeutic use , Drug Overdose , History, 21st Century , Humans , Male , Middle Aged , Parkinson Disease/history , Parkinson Disease/physiopathology , Psychomotor Performance/radiation effects , Retina/metabolism , Retrospective Studies , Sleep Initiation and Maintenance Disorders/therapy , Treatment Outcome
13.
Behav Brain Res ; 193(1): 37-47, 2008 Nov 03.
Article in English | MEDLINE | ID: mdl-18547659

ABSTRACT

Like enucleation, lateral hypothalamic (LH) lesions sever the connection between the retina and the pineal thereby simulating ambient exposure to constant darkness. While LH lesions have been employed to study either circadian function or Parkinson's disease (PD) independently, the application of such lesions to study circadian involvement specifically in this disease has never been attempted. In the present study, unilateral lesions of the LH, which compromise nigro-striatal dopamine (NSD) function, were combined with enucleation ipsilateral or contralateral to the hemisphere where 6-hydroxydopamine was applied. In addition to the observation that hemi-enucleation produced patterns of motor function that were grossly atypical compared to visually intact rats, hemi-enucleation ipsilateral to the side of NSD system denervation produced impairment of horizontal movement, limb retraction, ambulation and spontaneous or l-dopa induced turning. This impairment was more severe than that seen in rats with unilateral 6-OHDA lesions alone. Furthermore, hemi-enucleation contralateral to the side of unilateral NSD system denervation resulted in significantly improved performance on several parameters. While the rate of mortality in rats receiving unilateral 6-OHDA plus ipsilateral enucleation was similar to that occurring after bilateral lesions, it was not accompanied by severe weight loss and wasting that typically occurs in the acute stages of experimental PD. These results demonstrate the importance of the visual and circadian systems in PD and are consistent with reports that identify impaired circadian involvement as a major component in a wide range of neurological and neuropsychiatric conditions.


Subject(s)
Behavior, Animal/physiology , Circadian Rhythm/physiology , Functional Laterality/physiology , Hypothalamic Area, Lateral/physiopathology , Parkinson Disease/physiopathology , Substantia Nigra/physiopathology , Adrenergic Agents/administration & dosage , Adrenergic Agents/toxicity , Animals , Antiparkinson Agents/administration & dosage , Antiparkinson Agents/pharmacology , Behavior, Animal/drug effects , Circadian Rhythm/drug effects , Disease Models, Animal , Dopamine/physiology , Dose-Response Relationship, Drug , Eye Enucleation/adverse effects , Functional Laterality/drug effects , Hypothalamic Area, Lateral/drug effects , Hypothalamic Area, Lateral/pathology , Injections, Intraperitoneal , Levodopa/administration & dosage , Levodopa/pharmacology , Male , Motor Activity/drug effects , Motor Activity/physiology , Oxidopamine/administration & dosage , Oxidopamine/toxicity , Parkinson Disease/drug therapy , Parkinson Disease/etiology , Psychomotor Performance/drug effects , Psychomotor Performance/physiology , Rats , Rats, Sprague-Dawley , Severity of Illness Index , Stereotyped Behavior/drug effects , Stereotyped Behavior/physiology , Substantia Nigra/drug effects , Substantia Nigra/pathology
14.
Brain Res ; 1217: 119-31, 2008 Jun 27.
Article in English | MEDLINE | ID: mdl-18502399

ABSTRACT

Circadian involvement in Parkinson's disease (PD) and more specifically in nigro-striatal dopamine (NSD) function is of increasing interest to the neurosciences. Given that bright light therapy is of therapeutic value in PD, possible mechanisms underlying retinal involvement in this phenomenon was explored further by administering anti-Parkinsonian chemotherapies into the vitreus humour directly adjacent to the retina. 2 microl of a 100 mM solution of L-Dopa significantly improved motor function in the later stages of degeneration and during the day while the injection of 2 microl of a 10 mM solution of the melatonin receptor antagonist ML-23 improved motor function in the early stages of PD and during the dark phase of the light/dark cycle. The results suggest that the function of nigral cells is regulated by a more global system embracing circadian physiology that extends from the retina to the pineal. Furthermore, the induction of PD is characterised by an imbalance between melatonin and dopamine (DA) whereby this ratio is elevated at least 6 to 1 in favour of melatonin. The commonly observed treatment failures and side effects of DA replacement therapy probably result from increasing endogenous DA without taking parallel melatonin dysfunction into account. The proposed integrated function of the NSD and circadian systems may permit therapeutic targeting at a level which is safer, more effective and without the side effects of systemically administered regimens of DA replacement.


Subject(s)
Antiparkinson Agents/administration & dosage , Circadian Rhythm/physiology , Microinjections , Parkinsonian Disorders/drug therapy , Retina/drug effects , 5-Methoxytryptamine/administration & dosage , 5-Methoxytryptamine/analogs & derivatives , Animals , Circadian Rhythm/drug effects , Levodopa/administration & dosage , Male , Motor Activity/drug effects , Parkinsonian Disorders/physiopathology , Rats , Rats, Sprague-Dawley
15.
Rev Neurosci ; 19(4-5): 245-316, 2008.
Article in English | MEDLINE | ID: mdl-19145986

ABSTRACT

For more than 50 years, Parkinson's disease (PD) has been conceptualized as a product of nigro-striatal dopamine (NSD) system degeneration. In spite of a growing body of evidence depicting the mammalian brain as an interrelated complexity of circuitous systems, dopamine (DA) deficiency of the NSD is still regarded as the main problem, with DA replacement being the purpose of therapeutic intervention. For at least 191 years circadian involvement in various aspects of PD, including depression and insomnia, has been recognized as an integral part of the symptom matrix of PD and yet attempts to elucidate the involvement of this system is uncharted territory. The present review attempts a major reorganization of mammalian brain into a coordinated complex involving the NSD and the retinal hypothalamic tract (RHT) as the primary systems involved in the retino-diencephalic/mesencephalic-pineal (RDMP) axis. Secondary systems including the lateral hypothalamus (LH), the area postraema (AP) and the subthalamic nucleus (STN) also form an integral part of this system as they have been shown to be either intimately related to the primary systems of the RDMP axis or have been shown to be significantly involved in the expression and treatment of PD. A large volume of evidence suggests that the RDMP axis is activated during the course of PD and during therapeutic intervention. Four types of neurotoxicity associated with melatonin are identified and the susceptibility of various parts of the RDMP axis to undergo neuropathological change, the tendency for melatonin to induce PD-like behavioural toxicity, and the relationship of this to PD symptomotology are described. This includes adverse effects of melatonin on motor function, hypotension, the adjuvant use of benzodiazepines, depression, insomnia, body weight regulation and various biochemical effects of melatonin administration: all problems currently facing the proposal to introduce melatonin as an adjuvant. It is suggested further that traditional DA replacement may well work by exerting its effect upon the circadian system, rather than simply replacing deficient DA. Activation of the circadian function by antagonizing melatonin with bright light not only has therapeutic value in treating the primary symptoms of PD but it shares a common mechanism with L-dopa in reducing the occurrence of seborrheic dermatitis. Concepts at the centre of understanding pineal function in PD, including pineal calcification, melatonin deficiency, symptomatic versus protective features of melatonin and antioxidative effects, are explained in a counterintuitive context. Intriguing propositions including the role of the retina in the aetiology of PD and that the nigra functions as a retina in this disorder are presented with the intention to provide a new understanding of the underlying compromised function in PD and to provide new treatment strategies. For the first time, abundant evidence is presented describing PD as an endocrine disorder of melatonin hyperplasia. The role of circadian interventive therapies and internal desynchrony in the aetiology and progression of PD provides a new direction for understanding the underlying physiology of a disease which is currently in a state of impasse and provides new hope for those who suffer from its debilitating effects.


Subject(s)
Circadian Rhythm/physiology , Dopamine/metabolism , Endocrine System Diseases/complications , Melatonin/metabolism , Parkinson Disease/complications , Animals , Humans , Nerve Degeneration/physiopathology , Vision Disorders/etiology , Vision Disorders/pathology
16.
Chronobiol Int ; 24(3): 521-37, 2007.
Article in English | MEDLINE | ID: mdl-17612949

ABSTRACT

The antagonism of melatonin in models of Parkinson's disease (PD) can reduce the severity of motor impairment associated with dopamine (DA) degeneration. In consideration of the potent antidepressant effects of bright light therapy (LT), that LT suppresses melatonin secretion, that depression is commonly observed in PD, and that exposure to constant light facilitates recovery from experimental PD, the object of the present study was to strategically administer LT to PD patients and observe the effects on depression, insomnia, and motor performance. Twelve patients diagnosed with PD were exposed to white fluorescent light for 1-1.5 h at an intensity of 1000 to 1500 lux once daily commencing 1 h prior to the usual time of sleep onset, approximately 22:00 h in most patients. All patients were assessed before LT commenced and at two weeks, five weeks, and regular intervals thereafter. Within two weeks after commencing LT, marked improvement in bradykinaesia and rigidity was observed in most patients. Tremor was not affected by LT treatment; however, agitation, dyskinaesia, and psychiatric side effects were reduced, as verified by decreased requirement for DA replacement therapy. Elevated mood, improved sleep, decreased seborrhea, reduced impotence, and increased appetite were observed after LT. LT permitted the reduction of the dose of L-dopa, bromocriptine, or deprenyl in some patients by up to 50% without loss of symptom control. Factors limiting the efficacy of LT included multiple disease states, treatment compliance, polypharmacy, emotional stress, advanced age, and predominance of positive symptoms. The results of this case series study confirms previous work describing light as efficacious in the treatment of PD and suggest that controlled trials may help to elucidate how LT might be used strategically as an adjunct therapy to improve the morbidity of PD patients.


Subject(s)
Parkinson Disease/therapy , Phototherapy/methods , Aged , Aged, 80 and over , Delusions/chemically induced , Delusions/therapy , Depression/drug therapy , Depression/therapy , Dopamine/adverse effects , Dopamine/therapeutic use , Female , Hallucinations/chemically induced , Hallucinations/therapy , Humans , Hypokinesia/therapy , Interpersonal Relations , Male , Middle Aged , Muscle Rigidity/therapy , Parkinson Disease/drug therapy , Parkinson Disease/physiopathology , Psychomotor Performance/radiation effects , Sleep Initiation and Maintenance Disorders/therapy , Treatment Outcome , Tremor/therapy
17.
Drug News Perspect ; 18(7): 437-44, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16362083

ABSTRACT

Contemporary theory regarding the cause and treatment of neuropsychiatric disease strongly suggests that as the human body ages it gradually loses the intrinsic safeguards that protect it from oxidative damage. Melatonin is one hormone that serves this function in that it possesses antioxidative properties in the mammalian body and brain. Melatonin has been shown to prevent the progressive degeneration produced by neurotoxins employed in experimental models to mimic the degenerative events in various neuropsychiatric disease states. There are an abundance of models for numerous disease states demonstrating that melatonin can inhibit oxidative stress and by such a mechanism it is presumed to exert a therapeutic effect. While a similar scenario has been revealed with in vitro work relating specifically to Parkinson's disease, clinical work with melatonin in this disorder demonstrates that it is devoid of any remarkable therapeutic effects. More recent preclinical and clinical work has reliably demonstrated that melatonin in fact may be without therapeutic efficacy and may even worsen the condition. On this pretense, attempts to reduce the bioavailability of melatonin using a melatonin receptor antagonist have been found to completely restore behavioral and regulatory function in the presence of chronically reduced levels of dopamine, without producing side effects commonly seen with traditional dopamine replacement therapy. The unavoidable conclusion from this work suggests that within the dynamic framework of the mammalian brain, hormones may play a duel, and possibly ambivalent, role in homeostasis and in the etiology of disease. Such a position requires a reevaluation of the etiology, the role of dopamine, the neurochemical characteristics of Parkinson's disease and the validity of the models employed to study this and other neuropsychiatric disorders.


Subject(s)
5-Methoxytryptamine/analogs & derivatives , Antiparkinson Agents/therapeutic use , Levodopa/therapeutic use , Melatonin/antagonists & inhibitors , Parkinson Disease/drug therapy , 5-Methoxytryptamine/therapeutic use , Animals , Antiparkinson Agents/pharmacology , Disease Models, Animal , Humans , Levodopa/pharmacology , Melatonin/adverse effects , Melatonin/pharmacology , Parkinson Disease/etiology
18.
Behav Brain Res ; 160(1): 148-60, 2005 May 07.
Article in English | MEDLINE | ID: mdl-15836910

ABSTRACT

There are reports that melatonin secretion from the pineal gland gradually diminishes with advancing age. It has been suggested that various forms of neuropsychiatric disease, in particular, Parkinson's disease (PD), is consequentially related to this decrease by virtue of increased oxidative stress which enhances the process of dopamine (DA) degeneration. There is, however, considerable disagreement on this theme as very little is generally known about the role of the pineal gland in the aetiology and treatment of PD. To assess the role of the pineal gland in PD and in dopamine replacement therapy (DART), the effect of three anti-Parkinsonian drugs on motor and psychiatric function was assessed in normal, pinealectomized (PX) and DA deficient, PX rats. In the first study, rats underwent PX or sham operation and were then injected (IP) with Amantadine (30 or 50 mg/kg), Bromocriptine (5 or 10 mg/kg) or L-Dopa (30 or 60 mg/kg plus 50 mg/kg of R-044602) 3-8 weeks after surgery. Open field performance and motor reflex tests were assessed during the light and dark phases of the L/D cycle. In a second study, clinically effective doses of Bromocriptine (10 mg/kg) and L-Dopa (30 and 100 mg/kg with 50 mg/kg R-044602) were injected into depleted, PX or sham operated rats. In study I, sham operated and PX rats responded differently to Bromocriptine and L-Dopa, while Amantadine did not differentially effect motor performance in the two groups. In study II, 6-OHDA induced degeneration of the nigro-striatal system abolished the effects of Bromocriptine and dramatically altered the effects of L-Dopa seen in study I, in sham operated versus PX rats. DART significantly altered emotionality, as measured by escape attempts, agitation and rage in sham operated animals, compared to PX rats. DA deficiency abolished the tendency to escape in all groups except those treated with 100mg/kg of L-Dopa. Conversely, agitation and rage scores were greater after 100 mg/kg of L-Dopa, in rats with intact pineal function, than in PX rats. These results provide compelling evidence that altered pineal function plays a major role in the aetiology of PD, the therapeutic effect of anti-Parkinsonian drugs and in the psychiatric side effects of DART.


Subject(s)
Antiparkinson Agents/therapeutic use , Dopamine/deficiency , Parkinson Disease/drug therapy , Parkinson Disease/metabolism , Pineal Gland/physiology , Adrenergic Agents/toxicity , Analysis of Variance , Animals , Behavior, Animal/drug effects , Brain/anatomy & histology , Brain/drug effects , Brain/physiopathology , Disease Models, Animal , Dopamine/therapeutic use , Dose-Response Relationship, Drug , Drug Interactions , Male , Motor Activity/drug effects , Oxidopamine/toxicity , Parkinson Disease/etiology , Pineal Gland/surgery , Rats , Rats, Sprague-Dawley , Reaction Time/drug effects , Time Factors
19.
Pharmacol Biochem Behav ; 80(1): 9-26, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15652376

ABSTRACT

A new mechanism has been recently proposed, whereby melatonin may participate in the ongoing process of neuronal degeneration in models of neurodegenerative disorders, such as Parkinson's disease (PD). Antagonism of the melatonin receptor in rats using constant light or pinealectomy induced recovery and reduced the mortality typically associated with dopamine (DA) degeneration. In additional studies, employing ML-23 in the 6-OHDA-treated rat, remission from experimental PD was achieved using this drug in a post 6-OHDA treatment regime. To permit the further assessment of ML-23 as a potential clinical candidate for the treatment of PD, the present study was undertaken to determine the efficacy of ML-23 in the 1-methyl-4-phenyl, 1,2,3,6 tetrahydropyridine (MPTP) model in the common marmoset. ML-23 was administered orally in a dose of 3 mg/kg twice daily to half of the animals, while the other half received vehicle only, in a blinded protocol, for 56 days. The effects of the treatment on positive and negative features of MPTP-induced PD were assessed, including horizontal and vertical movement, head checking, general behaviour and Parkinsonian condition, raisin board performance, the ability to remove a foot label, palatable and dry food intake, water consumption, bradykinaesia, and the positive symptoms of tremor, obstinate progression, and agitation. On all parameters, ML-23 produced a significant remission from MPTP-induced Parkinsonism, and this effect did not abate when ML-23 treatment was withdrawn. In a further pilot study involving a crossover of two animals, one animal treated previously with MPTP plus vehicle showed some remission of negative and positive features, although ML-23 treatment was not commenced until 8 weeks post-MPTP. Conversely, a recurrence of Parkinsonian signs was not observed when ML-23 treatment was withdrawn and substituted with oral vehicle. Dopamine transporter was severely impaired in all marmosets treated with ML-23 or vehicle for the duration of the study. These results suggest that a novel mechanism involving melatonin is involved in the primary aetiology of the chronic aspects of PD, and such a mechanism is not related to the antioxidative function of this hormone. From these preliminary results, it is concluded that ML-23 and other melatonin analogues have an important role to play in the treatment and clinical management of Parkinson's disease.


Subject(s)
5-Methoxytryptamine/analogs & derivatives , 5-Methoxytryptamine/therapeutic use , Melatonin/analogs & derivatives , Parkinsonian Disorders/drug therapy , Parkinsonian Disorders/physiopathology , Recovery of Function/drug effects , 5-Methoxytryptamine/pharmacology , Animals , Behavior, Animal/drug effects , Behavior, Animal/physiology , Callithrix , Cross-Over Studies , Eating/drug effects , Eating/physiology , Male , Melatonin/antagonists & inhibitors , Reaction Time/drug effects , Reaction Time/physiology , Recovery of Function/physiology
20.
Pharmacol Biochem Behav ; 79(3): 413-29, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15582013

ABSTRACT

Over the past 10 years, there has been a resurgence of interest in examining the role of melatonin in health and disease. While the brunt of research in this area has portrayed melatonin in a favorable light, there is a growing body of evidence suggesting that melatonin may possess adverse effects contributing to the development of various neuropsychiatric disease states. In preclinical models of Parkinson's disease (PD), melatonin has been shown to enhance the severity of this condition while its antagonism, using constant light or pinealectomy, facilitates recovery. To test this hypothesis further, the present study employed the melatonin analogues ML-23 and S-20928 in a post-6-OHDA injection regime to determine whether they may have a favorable effect on the symptoms of this more chronic model of PD. When ML-23 was injected I.P. in a dose of 3 mg/kg twice daily for 3.5 days after 6-OHDA, significant improvement in motor function and regulatory deficits was observed. Similarly, the injection of S-20928 in a 1 mg/kg dose (I.P.), in the same regimen, facilitated modest improvement in motor function and regulatory deficits while the larger dose enhanced the severity of behavioural deficits and produced severe side effects causing deterioration in condition during the course of drug administration. ML-23 administration totally abolished the 6-OHDA-induced mortality, which accompanies dopamine (DA) degeneration, while S-20928 had no effect on this parameter. These results suggest that some melatonin analogues can aid in recovery from DA depleting lesions after DA degeneration has commenced and the recovery is not attributable to the antioxidative properties of this hormone. While the exact mechanism by which ML-23 and S-20928 are exerting their therapeutic effect is unclear, it is possible that antagonism of melatonin receptors may play some role and this should be considered when assessing the potential of melatonin analogues for treatment of human neuropsychiatric disorders.


Subject(s)
5-Methoxytryptamine/analogs & derivatives , 5-Methoxytryptamine/therapeutic use , Melatonin/analogs & derivatives , Naphthalenes/therapeutic use , Parkinsonian Disorders/drug therapy , Parkinsonian Disorders/physiopathology , Receptors, Melatonin/antagonists & inhibitors , 5-Methoxytryptamine/pharmacology , Animals , Male , Naphthalenes/pharmacology , Oxidopamine/toxicity , Rats , Rats, Sprague-Dawley , Receptors, Melatonin/physiology , Recovery of Function/drug effects , Recovery of Function/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...